Tandem and Eli Lilly carried out trials to demonstrate the advantages of using Lyumjev in combination with Control-IQ ...

Tandem Diabetes Care (NASDAQ: TNDM) had some encouraging news to report on the regulatory front Thursday, and after it hit ...

Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that ...

Tandem Diabetes Care (Nasdaq:TNDM) announced today that it received clearance for the use of rapid-acting insulin with its ...

The Federal Trade Commission (FTC) has filed a legal complaint accusing the 3 largest pharmacy benefit managers (PBMs) in the ...

The Tempo pen is currently compatible with three of Lilly's insulin products, including Humalog and Lyumjev, both insulin lispro-based, and insulin glargine brand Basaglar. "Despite technological ...

The militant group targeted areas in Israel farther south than most of its previous attacks, reinforcing fears of broader regional conflict. For Middle Eastern Foes, Diplomacy Takes a Back Seat to ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial ...

Although Lyumjev earned its approval in the 27-nation body back in 2020, the stringent testing the EU requires of pump manufacturers meant Tandem's product needed some time to catch up.